Peter A. Pinto, MD, presented “Focal and Salvage Therapies for Prostate Cancer: What’s Worth It and What’s Not?” at the 11th Urology Today conference on October 27, 2023.

How to cite: Pinto, Peter A. Focal and Salvage Therapies for Prostate Cancer: What’s Worth It and What’s Not?” October 2023. Accessed Jul 2024.

Focal and Salvage Therapies for Prostate Cancer: What’s Worth It and What’s Not? – Summary

Peter A. Pinto, MD, examines the current state of focal and salvage therapies for the treatment of prostate cancer, and offers his insights into which therapies are worth pursuing. He begins by addressing various kinds of salvage therapy, acknowledging that salvage therapy is a response to failed focal, radiation, or surgical therapy, and specifying that this presentation will focus on salvage therapy after failed radiation therapy.

Dr. Pinto explains that focal ablation therapy, whole gland ablation therapy, and surgical therapy are the most common salvage therapies after a radiation therapy failure. He recommends using an MRI-based biopsy method over more traditional methods to maximize accuracy in identifying lesions.

Dr. Pinto then recommends focal ablation over whole gland ablation as a salvage therapy after failed radiation therapy due to the high morbidity associated with whole gland ablation. Dr. Pinto concludes by listing the many ablation options for salvage therapy, and presents studies which examined the pros and cons of each option, offering his insights on each study.

About The 11th Urology Today Conference:

Presented by chair Ryan P. Terlecki, MD, FACS, the 11th Urology Today conference was designed to keep urologists, urologic oncologists, and other healthcare providers educated on the most pertinent issues in urology practices. Areas of focus included urologic oncology, men’s health and reconstruction, female urology, pediatric urology, kidney stones and related conditions, and methods of providing the best care amidst the required logistics of the business side of medicine.

For further educational activities from this conference, visit our collection page.


Peter A. Pinto, MD, is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute in Bethesda, Maryland. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute at Johns Hopkins Hospital in Baltimore, Maryland. Dr. Pinto is a board-certified urologic surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.